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CHAPTER 1 
A New Approach to Cancer Therapy: The Tumor 
Microenvironment as Target  
Reto A. Schwendener* and Sibel Mete 
Institute of Molecular Cancer Research, University of Zurich, Zurich, Switzerland 
Abstract: Solid tumors grow within a complex microenvironment composed of diverse 
cell types such as fibroblasts, endothelial cells, mast cells, macrophages and immune 
cells that are attracted by tumor cell derived factors and embedded in an extracellular 
matrix. Molecular and cellular interactions between epithelial cells and cells 
surrounding the tumor stroma promote growth, invasion and spread of tumors. To delay 
or impede tumor growth, the tumor microenvironment (TME) is increasingly being 
explored as a potential therapeutic target for which novel strategies are developed. 
This article reviews how key interactions between tumor cells and surrounding 
mesenchymal and immune cells in the TME can promote tumor progression and it 
highlights cellular and molecular elements that might represent novel therapeutic 
targets. Special emphasis is given on therapies targeted towards tumor-associated 
macrophages. As main class of drugs the bisphosphonates are covered with their 
properties to repolarize a pro-tumorigenic, immunosuppressive environment to a tumor 
growth inhibiting and immunocompetent microenvironment. Properties and advantages 
of liposome-encapsulated bisphosphonates as macrophage depleting or modulating 
agents as well as the latest developments towards clinical applications of compounds 
targeting cellular and molecular components of the TME are described and reviewed. 
Keywords: Adjuvant cancer therapy, bisphosphonates, clodronate, fibroblasts, 
immune cells, immunotherapy, liposomes, macrophage depletion, macrophages, 
myeloid derived suppressor cells, neutrophils, repolarization, reprogramming, 
stromal cells, stromal interactions, therapeutic targets, tumor associated 
macrophages, tumor associated neutrophils, tumor microenvironment. 
INTRODUCTION 
Cancer progression mostly depends on the ability of malignant cells to exploit 
physiological processes of the host. Solid tumors can only develop with a steady 
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supply of nutrients and oxygen, provided by blood and by support of cells, factors 
and conditions provided by the microenvironment [1-26]. Cells of the 
microenvironment become activated by communication with the tumor cells, 
consequently creating numerous conditions that promote cancer growth and 
ultimately lead to metastatic dissemination [5, 27-38]. 
First evidences about the effect of the host microenvironment on tumor growth 
were provided in the 1970s [39, 40] postulating that expansion from a single 
mutated cell to a solid tumor can only occur when the stromal environment is 
altered in a way to allow unrestrained tumor growth. Despite of continuous 
efforts, for many years cancer research largely focused on cancer-cell driven 
carcinogenesis and on understanding the mutations causing neoplastic cell 
transformations. This cancer cell centric view of tumor progression largely 
ignored the fact that complex interactions between cancer cells and stromal 
components tightly regulate and orchestrate tumor growth and metastatic 
dissemination. For this and other reasons, even after decades of implementing 
treatments that selectively target the tumor cell, survival of metastatic cancer 
patients is still disappointingly short. Therefore, novel strategies are urgently 
needed to complement the classical treatment modalities with new therapeutic 
approaches. In this regard, interactions between cancer cells and their host 
environment offer novel opportunities for therapies based on the improved 
understanding of the nature of these interactions and the mechanisms that govern 
them. Treatment modalities that target both cancer cells and components of the 
tumor microenvironment (TME) are likely to be more effective than those 
classically directed against cancer cells. A potential advantage in targeting the 
non-malignant cells of the TME is that these cells tend to be more genetically 
stable and are therefore less expected to develop resistance to therapies. 
To provide new therapeutic strategies targeted at the immune components of the 
TME, it is critical to understand how these cells are altered during tumor 
progression and how they reciprocally influence tumor initiation, progression and 
metastasis. Here, we review the current understanding of the interactions of tumor 
cells with the microenvironment with a particular focus on tumor associated 
macrophages (TAM), tumor associated neutrophils (TAN) and myeloid derived 
suppressor cells (MDSC) (Fig. 1). Current therapeutic approaches aiming at the 
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Characteristics and Components of the Tumor Microenvironment 
Angiogenesis, Hypoxia and Oxygen Regulation 
Angiogenesis is a key process for tumor development. Small colonies of 
malignant cells of 1-2 mm3 size, the so-called “carcinoma-in-situ”, alter their 
phenotype to induce continuous proliferation of endothelial cells and development 
of new blood and lymph vessels. This “angiogenic switch” triggers the expansion 
of the tumor cells by growth of new vessels that provide nutrients, oxygen and 
removal of waste products, as well as an escape route for metastasizing tumor 
cells [22, 24, 41-47]. 
Although various studies demonstrated that tumor cells produce pro-angiogenic 
factors, angiogenesis is also stimulated by activated myeloid cells recruited into 
the neoplastic tissue. Production of vascular endothelial growth factor (VEGF) is 
an important mechanism by which tumor infiltrating myeloid cells trigger and 
enhance angiogenesis and foster tumor development [48, 49]. TAMs are a major 
source of VEGF as they accumulate in poorly vascularized hypoxic areas and 
respond to hypoxia by releasing VEGF and other angiogenic factors (see below 
and Fig. 2). Hypoxic conditions in tumors stimulate the expression of pro-
angiogenic molecules by activating hypoxia-inducible factors (HIFs) in 
macrophages [19, 50-58]. Activated macrophages also release nitric oxide (NO), a 
molecule that provokes increased vascular flow [46, 59-64]. Myeloid derived 
suppressor cells (MDSC, see below) represent another cell population involved in 
tumor angiogenesis. Tumor cell educated MDSCs express elevated levels of the 
matrix degrading metalloproteinase MMP-9 that triggers VEGF release from the 
extracellular matrix (ECM) which induces proliferation of endothelial cells [65-
68]. Despite of their low abundance, tumor associated neutrophils (TANs, see 
below) have also been reported to support tumor growth by producing pro-
angiogenic factors such as VEGF, IL-8 and proteases including MMPs and 
elastase [65, 69-73]. In this context, it was found that Stat3 activation in tumor-
associated myeloid cells is critical for tumor angiogenesis [74]. Last but not least, 
pericytes, responsible for the stabilization of endothelial cells of the vessel wall, 
play a crucial role in hem- and lymphangiogenesis where they closely interact 
with endothelial cells and vascular smooth muscle cells [75-78]. Although the 
importance of myeloid cells in promoting tumor angiogenesis has been 
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investigated carefully, the underlying molecular mechanisms as well as the 
individual contributions of the different cell types remain to be fully explored. 
The Extracellular Matrix (ECM) and Regulation of Invasion and Metastasis 
The ECM serves as a scaffold for the cellular components of normal tissues as 
well as of tumors and it also strongly influences cell growth, differentiation, 
adhesion, motility, invasion and viability. The ECM consists of proteins that 
possess multiple functions and that provide vital signals for tumor progression and 
metastatic spread [79-85]. The matrix metalloproteinases (MMPs) with their 
proteolytic activity are key modulators of the TME and the most prominent family 
of proteases associated with tumorigenesis. They play an important role in ECM 
turnover and remodeling and in tumor cell migration. MMPs also control 
signaling pathways that regulate cell growth, inflammation and angiogenesis [86-
88]. The transmission of signals between the ECM and neighboring cells occurs 
mainly through the integrins. These proteins have the capability to transduce 
mechanical cues created by the ECM or the cell cytoskeleton into chemical 
signals that regulate many cellular processes such as proliferation, survival, 
migration, and invasion [80, 82, 84, 89, 90]. 
An important step in tumor progression is the acquisition of invasive properties by 
tumor cells. Epithelial-mesenchymal transition (EMT) is a well characterized 
mechanism, through which epithelial cells trans-differentiate and acquire an 
invasive, fibroblast-like phenotype [32, 91-95]. Although it is well established 
that the TME contains cytokines, growth factors and enzymes that induce EMT, 
the cellular sources of these factors remain to be fully identified. TAMs, cancer-
associated fibroblasts, CAFs, mesenchymal stem cells (MSCs) and lymphocytes 
have all been shown to contribute to an EMT promoting tumor microenvironment 
[95, 96]. Pro-inflammatory macrophages have likewise been shown to induce 
EMT at the invasive front, but also in the core of tumors, mainly through 
stabilization of Snail and Smad3, key mediators of EMT [97-99]. 
The ability of a growing tumor to invade tissue and to metastasize to distant 
organs was thought to be strictly cancer cell intrinsic. However, it is now 
established that tumor infiltrating and resident myeloid cells significantly 
contribute to tumor progression. Myeloid cell subsets as macrophages, MDSCs, 
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neutrophils and mast cells as well as soluble factors play an important role in 
ECM remodeling, invasion and metastasis which will be discussed in the 
forthcoming paragraphs. 
Chemokines and Cytokines 
The TME is rich in chemokines and cytokines which are vital factors for the 
regulation of tumor growth, invasion and metastasis. Most of resident and 
infiltrating cellular components of the TME contribute to a dynamic 
chemokine/cytokine network which is spatially and temporally fluctuating, 
depending on the local conditions of the TME. Beyond activating tumor 
vascularization, infiltrating myeloid cells also promote tumor growth by creating a 
microenvironment that is rich in growth factors and pro-inflammatory cytokines 
that stimulate proliferation and survival of neoplastic cells [26, 36, 70, 100-110]. 
Myeloid cell-derived cytokines and growth factors secreted by TAMs and 
MDSCs such as epidermal growth factor (EGF), platelet-derived growth factor 
(PDGF), fibroblast growth factor (FGF) and hepatocyte growth factor (HGF) all 
contribute to tumor growth [111]. Besides directly promoting tumor cell 
proliferation, tumor-educated myeloid cells can also indirectly facilitate tumor 
growth through suppression of anti-tumor immune responses by secretion of 
immunosuppressive cytokines, generation of reactive oxygen species (ROSs) and 
increased activity of arginase and nitric oxide (NO). Another important 
immunosuppressive mediator, TGF- converts naive CD4+ T cells to adaptive 
regulatory T cells [112, 113]. 
Fibroblasts and Mast Cells 
Cancer associated fibroblasts (CAF) are a heterogeneous cell population. The main 
progenitors of activated fibroblasts in the TME are originating from resident 
fibroblasts. CAFs can also stem from pericytes, smooth muscle cells and from bone 
marrow derived mesenchymal cells [114, 115]. CAFs contribute to a pro-tumorigenic 
environment through interaction with other cells in the TME. They are regulators of 
tumorigenesis and they differ from tumor cells by being more genetically stable. CAFs 
have properties to enhance tumor angiogenesis by secretion of stromal cell-derived 
factor 1 (SDF-1), also known as CXCL12, which plays a central role in the promotion 
of tumor growth and angiogenesis [116]. Besides that they produce many growth 
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factors (HGF, VEGF, TGF-β), cytokines (IL-8, CXCL14, CCL7, IL-6, IL-1α), 
proteases (MMPs, uPA) and other enzymes [117]. The clinical relevance of CAFs 
tumor growth promoting role has also been recognized by exploiting CAF expressed 
factors as prognostic markers [114, 116, 118-122]. 
Mast cells (MC) are derived from the bone marrow and are also a heterogenous 
cell population with many functions. Apart from their role in innate and adaptive 
immunity they influence tumor cell proliferation and invasion and modulate the 
immune responses to tumor cells [123]. The number of tumor infiltrating mast 
cells correlates with increased intratumoral microvessel density, enhanced tumor 
growth and invasion, and poor clinical outcome. MCs are predominantly located 
at the boundary between healthy tissues and the TME and are often found in close 
association with blood vessels. They support angiogenesis by expression of pro-
angiogenic factors and by inhibition of ECM remodeling the MCs support tumor 
spread and metastasis. Tumor-associated mast cells are also regarded as potential 
therapeutic targets [124-128] and prognostic factor [129-131]. 
Leukocytes 
Leukocyte infiltration into malignant tissue was first described by the pathologist 
Rudolf Virchow in 1863 [132]. Solid tumors contain various types and numbers of 
leukocytes that can represent up to 50% of the tumor mass. The major components 
of the leukocytic infiltrates in the TME are myeloid cells and B and T lymphocytes 
[38, 133] as well as regulatory T cells [134-138]. Specifically, myeloid cells are the 
major component of the leukocytic infiltrates found in tumors. Immune cell 
infiltration into tumors and the impact the immune cells have on cancer has been 
named cancer immunoediting or cancer immunosurveillance. This concept that 
describes the role the immune system plays in cancer development was considered 
and discussed throughout the last decades. The central principle is that the immune 
system can prevent tumor development but that it is also able to select tumor variants 
with reduced immunogenicity, and creating an inflammatory environment that 
provides tumors with mechanisms to escape immune detection and elimination [139-
146]. Initially, the presence of leukocytes in malignant neoplasms was thought to 
represent the host’s immune response to a growing tumor [147]. Yet, solid tumors 
are mostly recognized as “self” and they do not evoke efficient immune responses 
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capable of eradicating tumors [148, 149]. In contrast, it was found that these cells are 
actively recruited to neoplastic tissues by tumor cells and that high numbers of 
several types of leukocytes are associated with tumor progression [38, 150-152]. 
Nevertheless in some cancers, the presence of leukocytes is associated with a 
favorable prognosis [153]. For example, enhanced infiltration of natural killer cells 
and cytotoxic T cells into tumors has been reported to correlate with a good 
prognosis in human ovarian, colorectal and gastric cancers [154, 155]. Similarly, 
cytotoxic activation of lymphocytes, particularly CD8+ T cells in response to tumor 
growth result in regression [156]. In contrast, as described in more details below, 
tumor-activated myeloid leukocytes (TAMs, DCs, MDSCs) are known to restrain 
the protective function of these immune cells with anti-tumor activity and to promote 
tumor growth. 
Macrophages 
Macrophages belong to the mononuclear phagocyte system (MPS) which are cells 
involved in host defense functions, immune reactions, disposal of dead cells and 
cellular components and synthesis of biologically active compounds such as 
complement components and prostaglandins [157-159]. The MPS includes precursor 
cells in the bone marrow, blood monocytes, alveolar, peritoneal and splenic 
macrophages and Kupffer cells in the liver. Macrophages are extremely versatile 
cells that can adapt a particular phenotype depending on environmental stimuli. As 
most of the other cell types that populate the TME, they produce an assorted array of 
chemokines, cytokines, proteases, angiogenic and other growth factors. As unique 
property they possess the ability to phagozytose particular matter as dead cells, 
bacteria, viruses as well as artificial particles like liposomes, nanoparticles and other 
pharmaceutical drug carriers [157, 160-173]. Macrophages play a very important 
role in tumor development as they are a major component of the myeloid infiltrate in 
a tumor microenvironment. 
Hence, of all cells of the myeloid lineage, they are among the most studied for 
their contribution to tumor development. Monocytes circulating in the blood are 
recruited to tumors by tumor-derived chemotactic factors such as the colony 
stimulating factors M-CSF and GM-CSF (macrophage and granulocyte-
macrophage colony stimulating factor), CCL2 (chemokine C-C motif ligand 2,  
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Figure 2: TAM can localize within unique tumor microenvironments. The immunofluorescent 
confocal micrograph in the center shows red stained F4/80+ macrophages within a late-stage tumor 
of mammary carcinogenesis in the MMTV-PyMT mouse model. Areas of hypoxia are shown in 
yellow, functional vasculature is stained in green and all cell nuclei are stained in blue with DAPI. 
Insets display enlarged graphical representations of TAMs within a hypoxic region, at an invasive 
front, in a normoxic area within the tumor, and associated with the vasculature. Adapted from 
TRENDS in Immunology with permission [192]. 
MCP-1) and VEGF. Upon migrating into the tumor the monocytes differentiate 
into tissue-resident macrophages termed tumor-associated macrophages (TAMs) 
[38, 46, 59-63, 98, 174-191]. The term TAM defines localization of macrophages 
at the tumor-stroma interface and in the tumor core. As depicted in Fig. 2, TAMs 
localize at different sites in a tumor where they assume different functions that are 
driven by signals they obtain from the particular microenvironment in which they 
are located [192]. In response to diverse stimulants in the TME, TAMs undergo 
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therefore they are endowed with an enhanced ability to kill tumor cells. In 
contrast, when TAMs are exposed to anti-inflammatory molecules, such as the 
interleukins IL-4, IL-10, IL-13 or glucocorticoid hormones and other factors, they 
are polarized to the opposite extreme called M2. M2-TAMs are poor antigen 
presenting cells and they support tumor growth, angiogenesis, and metastasis. 
Conversely, TAMs suppress the immune system by responding to anti-
inflammatory cytokines, apoptotic cells and immune complexes. M1 macrophage 
activation is characterized by high levels of major histocompatibility complex 
class II (MHC-II) expression and antigen presenting capacity, high production of 
pro-inflammatory cytokines such as IL-1, IL-12, IL-23, TNF- and of toxic 
inducible nitric oxide synthase (iNOS) and reactive oxygen intermediates (ROI). 
In contrast, the M2 activation state is characterized by an IL-10high and IL-12low 
phenotype, expression of low levels of MHC-II and increased production of 
angiogenic factors and anti-inflammatory cytokines like IL-10, arginase and TGF-
. Furthermore, M1 macrophages express opsonic receptors (e.g. FcγRIII), 
whereas M2 macrophages preferentially express non-opsonic scavenger receptors 
such as the mannose receptor (MR) and CD163 [193-195]. In the majority of solid 
tumors TAMs predominantly are of the M2-phenotype. They promote 
angiogenesis (see Fig. 3) and express high levels of M2-markers (IL-10, TGF-β, 
ARG1, CD163, MR) and low levels of mediators of inflammation (IL-6, IL-12, 
iNOS and TNF-α) [181, 185, 186, 196-198]. 
This discrimination between M1 and M2 macrophages is a rather simplified view 
of two extremes of polarization and it does not fully represent the continuum of 
functional states of macrophages in the TME. Not only the intratumoral 
macrophages, but also spleen and peritoneal macrophages of tumor-bearing 
individuals share these similar immunosuppressive properties and play an 
important role in tumorigenesis [199, 200]. TAMs were also shown to attract 
CD4+CD25+FOXP3+ regulatory T cells [112] that are known to suppress the anti-
tumor function of cytotoxic T cells. Accumulation of Treg in tumors is a common 
feature of human cancers and the abundance, as well as their suppressor activities 
are highly correlated with a poor disease prognosis. In ovarian carcinoma it was 
found that TAMs regulate Treg trafficking to tumors by producing CCL22, a 
chemokine that mediates regulatory T cells recruitment [201]. 
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Numbers, polarization state and cytokine expression pattern of TAMs can be 
correlated in several cancer types with the clinical prognosis of the disease [38, 
185, 202]. For example, high numbers of TAMs are, among others, indicative of 
bad prognosis in colorectal cancer [203, 204], non small cell lung cancer 
(NSCLC) [98, 205-207], Hodgkin’s lymphoma [208], breast cancer [209, 210], 
liver cancer [211, 212] and prostate cancer [213]. 
Analysis of the molecular basis of the TAM phenotype identified components of 
the NF-B signaling system as one of the main players in the modulation of 
macrophage function [214-216]. For example, NF-B inhibition by targeted 
deletion of IKK- in TAMs increased their anti-tumor activity through reduced 
production of arginase-1, IL-10 and TNF- with concomitant increased 
production of iNOS and IL-12, suggesting that IKK- signaling in macrophages 
maintains their alternative tumor-promoting phenotype [217]. On the contrary, in 
more advanced stage tumors, a therapeutic effect was achieved through the 
restoration of NF-B activity in myeloid cells [218, 219]. These divergent results 
may be associated with progressive modulation of NF-B activity in tumor-
infiltrating macrophages. Other important modulators of macrophage polarization 
are members of the STAT family of transcription factors. Although earlier 
evidence indicated that the STAT1 activation regulates the M1 activation of 
macrophages, recent reports argue that activated STAT1 may induce TAM-
mediated suppressive activity and tumor progression [220-222]. In addition, 
STAT3 and STAT6 activation were also shown to be associated with M2 
macrophage polarization [223, 224]. The interplay of TAMs with immune cells 
(B-cells, T-cells, regulatory T-cells and neutrophils) will be described and 
summarized in the respective paragraphs below. 
Dendritic Cells 
The second cell type that belongs to the mononuclear phagocyte system (MPS) 
are the dendritic cells (DC). DCs are bone marrow-derived cells originating from 
both lymphoid and myeloid progenitors. They populate all lymphoid organs 
including the thymus, spleen, and lymph nodes, and comparable to the 
macrophages, nearly all non-lymphoid tissues and organs. DCs have potent 
antigen-presenting capacity for the stimulation of T cells and they also belong to 
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the innate immune system where they respond as immature cells to danger signals 
in the microenvironment by differentiating and acquiring the capacity to mount 
primary immune responses. DCs possess powerful adjuvant activity as they have 
the ability to stimulate specific CD4 and CD8 T cells [38, 180, 225-231]. This 
property has made them attractive targets in vaccine development strategies for 
the prevention and treatment of infections, allograft reactions, allergic and 
autoimmune diseases and cancer. A major use of DCs as immunotherapeutic 
vaccines consists in their ex vivo priming combined with adjuvant treatments that 
eliminate immunosuppressive mechanisms in the TME (see below). 
Similar to TAMs, the dendritic cells are also infiltrating tumor tissue following 
chemokine signals released by the TME. These tumor-associated dendritic cells 
(TADC) share many properties with TAMs as they can also be polarized either to 
tumor-suppressive “M1-like” or to tumor-promoting “M2-like” phenotypes [38, 
231-233]. 
Myeloid Derived Suppressor Cells (MDSC) 
Myeloid derived suppressor cells (MDSCs) are another complex but well 
characterized population of tumor-infiltrating myeloid cells that negatively affect 
the anti-tumor immune response. MDSCs are a heterogeneous population of cells 
comprised of monocyte, granulocyte and dendritic cell precursors and myeloid 
cells at an early stage of differentiation [67, 234-241]. These cells are defined by 
the co-expression of the monocytic marker CD11b and the granulocyte 
differentiation antigen Gr1 (constituted by the epitopes Ly6C and Ly6G in mice). 
In recent studies MDSCs were broadly classified as two major subsets, namely 
cells of granulocytic (CD11b+Ly6G+Ly6Clow) and monocytic (CD11b+Ly6G-
Ly6Chigh) phenotype [242, 243]. 
It has been well established that the frequency of these cells significantly 
increases in the spleen and bone marrow of tumor-bearing mice, as well as in the 
peripheral blood and tumors of cancer patients [241]. In naive tumor-free mice, 
MDSCs constitute approximately 30% of all bone marrow cells and 3% of all 
nucleated splenocytes. However, in tumor bearing mice, they may represent more 
than 20% of all splenocytes [238]. In both patients and experimental animals, 
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MDSCs have been shown to be mobilized from bone marrow in response to 
multiple tumor-derived factors such as Bv8 and endocrine gland-derived VEGF 
[244, 245]. Their recruitment to tumors is mediated by chemotactic factors like 
CCL2/MCP-1, CXCL12/SDF-1, CXCL5 and KIT ligand [246]. Although 
MDSCs are able to differentiate into mature myeloid cells upon exposure to 
appropriate stimuli, their differentiation is blocked by tumor cell conditioned 
media in vitro or in a tumor-bearing host in vivo [247]. These immature myeloid 
cells potently suppress maturation and anti-tumor activation of dendritic cells, T 
cells and natural killer cells, a phenotype that provides the most effective way of 
identifying MDSC [248]. Hence, injection of tumor cells in combination with 
CD11b+Gr1+ cells in mice prompt tumor growth [249]. Accordingly, depletion of 
Gr1+ cells in tumor-bearing mice leads to delayed tumor growth, suggesting 
MDSC as potential targets for anti-cancer therapy [250-256]. A report by Youn 
and colleagues indicated that CD11b+Gr1+ cells from naïve tumor-free mice are 
not immune suppressive [243]. However, it is not yet fully known why 
CD11b+Gr1+ cells isolated from tumor-free and tumor-bearing animals exhibit 
different functions. A recent study suggested a HIF-1 mediated regulatory 
mechanism for the biological dichotomy displayed by MDSCs within the TME. 
These researchers demonstrated that splenic MDSCs of tumor bearing animals 
cause ROS mediated antigen-specific T cell unresponsiveness, whereas 
intratumoral MDSCs with similar morphology and phenotype suppress both 
antigen specific and nonspecific T cell function through elevated NO levels and 
arginase I production [257]. 
Neutrophils 
Neutrophils are short-lived white blood cells derived from bone marrow myeloid 
progenitors. During infection-related immune responses neutrophils are among 
the first cells to arrive at the site of infection where they release chemokines and 
proteases that trigger the recruitment of both innate and adaptive immune effector 
cells. Neutrophils also release cytotoxic mediators, including reactive oxygen 
species, membrane-perforating agents, proteases and soluble mediators such as 
interferons, TNF- and IL-1, suggesting their potential anti-tumor activity [72, 
258, 259]. Generally, in most tumors low numbers of neutrophils are found. Both 
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cancer cells and cells of the TME actively recruit neutrophils by means of 
secreted chemotactic factors, in particular G-CSF, GM-CSF, CXCL2/MIP-2, 
CCL3/MIP-1, CXCL5/LIX and CXCL1/KC. Upon recruitment to the tumor site, 
neutrophils can assume tumor growth-stimulatory or -inhibitory functions [71]. In 
human tumors, an increased density of tumor-infiltrating neutrophils was found to 
correlate with a poor prognosis in patients with adenocarcinoma and metastatic 
melanoma, whereas in few cases like gastric carcinoma neutrophil infiltration was 
linked to beneficial disease outcome [260-262]. This discrepancy is probably 
related with the degree of neutrophil recruitment and their differential activation, 
depending on the intratumoral cytokine microenvironment in which they reside. 
Similar to TAMs, the functional status of tumor associated neutrophils (TANs) 
regulates their ability to express an anti-tumor potential. Accumulating 
experimental and clinical evidence also confirms that neutrophils can polarize in a 
type I or type II direction in tumors. Recently, Fridlender and colleagues 
characterized N1- and N2-polarized phenotypes of TANs, similar as described for 
TAMs [263]. In lung and mesothelioma tumor models, TANs were shown to 
acquire a N2-phenotype. The pro-tumorigenic activities of N2-TANs include 
increased production of immunosuppressive cytokines and reduced cytotoxic 
activity. This pro-tumor phenotype of neutrophils was found to be induced and 
maintained by TGF- [264]. N1-polarized neutrophils exert anti-tumor activities 
indirectly as well by promoting recruitment and activation of CD8+ T cells. In 
addition to induction of the anti-tumor N1-polarization, blocking of the TGF- 
pathway caused increased recruitment of Ly6G+ neutrophils in tumors [263]. This 
finding is consistent with studies that demonstrated an enhanced influx of myeloid 
cells into mammary carcinomas deficient in type-II TGF- receptor [249]. 
Further, it was shown that abrogation of TGF- signaling in human breast cancer 
cells enhanced the production of the neutrophil chemoattractants CXCL1 and 
CXCL5 [265]. Apparently, TGF- is one of the major players in regulating 
neutrophil recruitment and activation in the TME. A recent study suggested that 
constitutive expression of IFN- counteracts the cancer-supportive function of 
neutrophils by inhibiting expression of genes encoding pro-angiogenic and 
homing factors in these cells [266]. 
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component of the TME, the tumor promoting properties of myeloid cells render 
these cell types as valuable tools and targets for therapeutic interventions. One of 
the first strategies that have been explored since many years is the adoptive 
immunotherapy which consists in the transfusion of host derived and in vitro 
activated or engineered lymphoid cells. Transfer of tumor infiltrating leukocytes 
(TIL) to tumor bearing hosts mediates antitumor responses and several myeloid 
cell subpopulations were found to be suitable for use in adoptive immunotherapy. 
Lymphocytes treated with IL-2 give rise to lymphokine activated killer (LAK) 
cells that have the ability to lyse malignant but not normal cells. Clinical studies 
in patients with advanced cancer revealed that treatment with IL-2 alone or in 
combination with LAK cells mediate complete or partial regression of cancer, 
predominantly melanomas [269-273]. Other methodologies either used 
combinations of lymphokines, such as TNF-α or interferons in conjunction with 
IL-2 or gene therapy approaches to further improve the effects of adaptive 
immunotherapy [274-278]. Although the significance of MHC class I-restricted 
cytotoxic T lymphocytes (CTLs) as effectors of anti-tumor immunity has widely 
been demonstrated, most human tumors lack MHC-I expression or are 
inadequately differentiated and poorly immunogenic, a culprit that limits 
successful T-cell based tumor-specific immunotherapy [279]. In another cell-
based therapy approach efficient tumor-specific effector and memory T cells are 
induced through therapeutic vaccination. Such vaccines follow two purposes, 
namely priming antigen-specific T cells and reprogramming memory T cells by 
transforming them from the immunosuppressive to the immunostimulating and 
cytotoxic phenotype. Dendritic cells (DCs) are very potent antigen presenting 
cells and thus essential in generation of immune responses, and they therefore 
represent valuable targets and vectors for cancer vaccination [280-293]. 
Therapies Aimed at TAMs 
Based on the M1 versus M2 paradigm of macrophage polarization, inhibition of 
M2- and activation of M1-inducing signals was suggested as a potential strategy 
to re-establish the anti-tumor function of macrophages [294]. Indeed, 
pharmacological skewing of macrophage polarization from the M2- to M1-
phenotype is able to induce an anti-tumor activity. Co-administration of the 
macrophage chemoattractant CCL16 with a CpG oligonucleotide and an anti-IL-
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10 receptor antibody was shown to skew M2-TAMs to M1-TAMs that triggered 
an innate response resulting in the regression of pre-established tumors [295]. 
Similarly, combination of an anti-CD40 antibody with CpG oligonucleotides and 
multidrug chemotherapy induced antitumor effects by TAM polarization [296]. 
Considering the central role the statins play in myeloid cell polarization, members 
of the STAT family of transcription factors are valuable targets for the modulation 
of myeloid cells. To this end, tumor bearing STAT6-/- mice were shown to display 
an M1-TAM phenotype and to reject a spontaneously growing mammary 
carcinoma [297, 298]. Accordingly, it was found that the SHIP1 phosphatase 
plays an important role in macrophage re-programming. Mice deficient in SHIP1 
displayed a skewed development toward M2-TAM and thus pharmacological 
modulators of this phosphatase could be developed [299]. More recently, a host-
derived factor, histidine-rich glycoprotein (HRG) was reported to promote M1 
polarization of TAMs by downregulation of PLGF [300]. 
Other approaches aim at the depletion of TAMs, either by blocking vital functions 
of the cells or by their physical depletion. In various models it was shown that 
blockade of the macrophage specific colony-stimulating factor 1 (CSF-1) or its 
receptor CSF-1R suppresses macrophage infiltration and tumor growth [301-303]. 
The physical (pharmacological) depletion of macrophages from organs of the 
MPS using the bisphosphonate clodronate encapsulated in liposomes (Clodrolip) 
has become an important, reliable and widely used method to study not only the 
role of macrophages in the immune system and in inflammatory processes but 
also in tumor growth and metastasis [304-311]. 
Bisphosphonates 
Bisphosphonates (BPs) are inorganic pyrophosphate analogs (PPi) that effectively 
inhibit osteoclastic bone resorption and are widely used to treat metabolic bone 
diseases, such as postmenopausal osteoporosis [312], Paget's disease [313], tumor 
associated osteolysis [314] and to prevent bone metastasis [315]. The high affinity of 
the BPs for the calcium component of the bone matrix hydroxyapatite is the cause of 
the bone-specificity of these compounds. Organ distribution studies demonstrated 
that BPs are mainly localized in newly formed bones and internalized by the bone 
resorbing osteoclasts where they inhibit their activity [316]. Due to their high affinity 
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for bone matrix, systemic availability of BPs is rather low with the exception of a 
transient raise of plasma levels in the post-administration period [317]. 
Based on their chemical structure BPs can be divided into two distinct 
pharmacological classes; the nitrogen-containing bisphosphonates, (N-BPs, e.g. 
zoledronate) and the first-generation BPs, the non-nitrogen-containing 
bisphosphonates (non-N-BPs, e.g. clodronate, see Fig. 5) that chemically 
resemble pyrophosphate (PPi). Pyrophosphate has a P–O–P structure, whereas the 
BPs have a P–C–P structure where the central oxygen atom is replaced by a 
carbon atom. The most important first generation non-N-BP bisphosphonate, 
clodronate has R1 and R2 side chains with two chlorine atoms, whereas the N-BP 
zoledronate carries a hydroxyl group on R1 and an imidazolyl group on R2. BPs 
containing nitrogen atoms in the R2 side-chain like zoledronate are significantly 
more potent than non-N-BPs [317]. The mechanism of action of the BPs differs 
according to their chemical structure. After cellular uptake, non-N-BPs are 
metabolized to cytotoxic analogs of adenosine triphosphate (ATP) causing cell 
death by apoptosis [318]. The N-BPs exert their effects mainly by inhibiting a key 
enzyme in the mevalonate pathway, the farnesyl pyrophosphate synthase (FPP 
synthase), thereby preventing the synthesis of isoprenoid compounds that are 
essential for the post-translational modification of small guanosine triphosphate 
(GTP)-binding proteins such as Rab, Rho, and Rac [319]. Recent studies revealed 
that N-BPs can also induce formation of a new pro-apoptotic ATP analog that 
induces mitochondria-mediated apoptosis [320]. 
Although the most effective N-BP zoledronate has originally been developed to 
inhibit osteoclast mediated bone resorption, the anti-cancer effects of this compound 
are currently being evaluated. In this context zoledronate is used as adjuvant therapy 
to inhibit local bone destruction by tumors and to prevent or delay metastasis to bone 
[321-323]. Moreover, zoledronate has demonstrated significant clinical benefits in 
patients with metastatic prostate and lung cancer [322, 324, 325]. Zoledronate exerts 
these anti-tumorigenic activities directly on cancer cells by modulating their 
tumorigenic properties and indirectly on stromal cells by changing their tumor-
promoting properties. One of the major anti-tumor effects of zoledronate is the 
induction of apoptosis but the drug also interferes with migratory and invasive 
properties of tumor cells [326-329] and with angiogenesis [330-332]. In addition to 
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its pharmacological effects, zoledronate has immune modulatory activities that 
include stimulation of proliferation and activation of the V9V2 subset of T cells. 
T cells expressing the V9V2 T cell receptor play a significant role in immune 
surveillance and defense [333-335]. These cells have the ability to recognize and kill 
tumor cells in an MHC-independent manner, suggesting their potential utility in the 
elimination of cancer cells with poor antigen presentation capacity [336]. Several 
pre-clinical studies have shown that V9V2 T cells expanded in vitro sustain their 
anti-cancer activity upon adoptive transfer into mice transplanted with various 
human cancer cells along with zoledronate treatment [337-340]. Clinical studies also 
demonstrated expansion and activation of V9V2 T cells to a subset of IFN-γ 
producing effector T cells in patients treated with zoledronate, either alone or in 
combination with IL-2 [337, 341, 342]. Besides cancer cells, monocytes treated with 
zoledronate were also shown to stimulate proliferation and cytotoxic activation of 
human V9V2 T cells. Notably, activation of T cells requires cell-to-cell contact 
with zoledronate treated tumor cells or monocytes [343]. Among several growth 
factors, TGF-β is known as the most abundant cytokine in bone and considered as 
the main bone-derived factor responsible for driving this vicious cycle of bone 
metastasis [344]. Activated TGF-β is released from mineralized bone matrix and in 
turn it induces production of tumor-derived osteolytic factors [345-349]. 
These and other data suggest that modulation of bone derived factors like TGF-β 
might also be a possible mechanism responsible for the anti-tumor activity of 
zoledronate. Altogether, pre-clinical and clinical studies suggest multifaceted anti-
cancer effects of zoledronate in different tumor types. In addition, clinical studies 
showed that zoledronate prolongs disease-free survival in cancer patients [350]. 
However, the identification of new cellular targets and further elucidation of the 
cellular and molecular mechanisms by which zoledronate mediates anti-tumor 
effects will be useful in the design of new therapeutic strategies to modulate and 
potentiate the anti-tumor effects of this compound. 
Depletion of TAMs with Clodronate-Liposomes (Clodrolip) 
Exploiting the anti-tumor properties of the bisphosphonates and in particular 
clodronate-liposomes, we examined the possibility whether depletion of TAMs 
would inhibit tumor angiogenesis and tumor growth. In our experiments, we 
showed for the first time that treatment of tumor bearing mice with Clodrolip as 
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Table 1: Effects on Tumor Growth by Clodrolip mediated Depletion of TAMs in select preclinical 
Tumor Models 
Models (Tumor cells, 
treatments)  
Effects of TAM Depletion Notes Refs. 
Breast cancer (MDA-
MD-231, MVT-1) 
overexpr. S100A7  
 Inhibition of the effects of 
S100A7 induction on tumor 
growth and angiogenesis in 
orthotopic models.  
S100A7 is overexpressed in invasive 
estrogen receptor α-negative breast 
cancer and activates pro-
inflammatory pathways. 
[363] 
F9 teratocarcinoma in 
Sv129 mice  
Depletion correlated positively 
between TAM-densities and 
mesenchymal marker expression. 
TAMs induce EMT through TGF-β 
signaling and β-catenin activation. 
Clinical relevance is shown in non-
small cell lung cancer (NSCLC). 
[98] 
Lung cancer induced by 
urethane in FVB mice 
Alveolar macrophage depletion 
reduced number and size of lung 
tumors and inhibited 
angiogenesis. 
Urethane treatment induced M1 
macrophages (first 2-3 wks) 
followed by M2 macrophages by 
week 6.  
[364] 
Bladder cancer (MBT-2)  
TAM depletion by Clodrolip or 
VEGF block inhibited 
lymphangiogenesis and lymph 
node metastases but not growth 
of orthotopic primary tumors. 
Massive lymphangiogenesis and 
TAM infiltration in primary tumor 
and metastasis in lymph nodes. 
[365] 
Liver cancer (Hepa 1-6) 
TAM depletion reduced tumor 
growth in s.c. and othotopic liver 
tumors. 
TAMs express MHC-IIhigh at early 
stages and pro-tumorigenic MHC-
IIlow during tumor growth.  
[366] 
Hepatocellular cancer 
xenografts, sorafenib 
treatm. 
TAM depletion or zoledronate 
(zol) + sorafenib inhibited tumor 
progression, angiogenesis and 
lung metastasis.  
Combined therapy with zol or TAM 
depletion enhanced the effect of 
sorafenib. Zol was more effective 
than Clodrolip. 
[354] 
Melanomas in C57BL/6 
and TNFR1,2−/−, TNF−/− 
mice, local radiation 
therapy 
TAM depletion before 
radiotherapy increased antitumor 
effects of ionizing radiation in a 
TNFα dependent way. 
Treatment with a TNF receptor 
fusion protein (Enbrel) showed that 
macrophage mediated 
radioresistance required intact TNFα 
signaling. 
[367] 
Colon adenocarcinoma 
(MC38), mammary 
tumors (AT-3, 4T1.2) 
targeting DR4 and DR5 
with mab MD5-1 
MD5-1 mab treatment inhibited 
tumor growth by TRAIL-R 
dependent tumor cell apoptosis. 
Clodrolip treat-ment enhanced 
efficacy of MD5-1.  
Ab-mediated targeting of DR5 
triggers tumor cell apoptosis in a B 
cell-dependent manner. Contribution 
of NK cells, CD11b+ cells, and 
macrophages to the antitumor effects 
of MD5-1. 
[368] 
Colon adenocarcinoma 
(MC38), renal cell 
carcinoma (Renca) 
combination of CpG 
1826 with a CD137 
specific T-cell antibody  
CpG plus anti-CD137 caused 
tumor regression. TAM depletion 
enhanced therapy leading to 
tumor rejection in 100% of mice.  
This study provides support for the 
use of a novel combination of 
immunomodulatory agents 
stimulating multiple facets of 
immunity for the effective 
immunotherapy of cancer.  
[369] 
HPV16 E6- and E7-
expressing TC-1 mouse 
tumor model 
TAM depletion inhibited tumor 
growth and stimulated HPV16 
tumor infiltration by virus-
specific CD8 lymphocytes.  
M2-like macrophages infiltrate 
HPV16-associated tumors causing 
suppression of antitumor T-cell 
response. 
[370] 
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Table 1: contd…… 
Ovarian carcinoma 
(MDAH-2774, SKOV-3, 
OVCAR3) in nude mice 
Depletion of macrophages by 
Clodrolip markedly reduced 
lymph-angiogenesis. 
Blockade of VEGF/VEGFR 
signaling or depletion of 
macrophages reduced lymph-
angiogenesis. 
[371] 
Lung cancer (HARA-B) 
injected into the left 
cardiac ventricle of mice 
Clodrolip significantly reduced 
the number of macrophages in 
tumors and osteoclasts in bone 
marrow. 
Clodrolip exerted antimetastatic 
effects in both bone and muscle. [372] 
Rat glioma (D74/HveC), 
oncolytic viruses (OV) 
injected into intracranial 
gliomas 
Depletion of TAMs enhanced 
intratumoral OV spread. 
CD163+ macrophages infiltrated the 
tumor. TAM depletion during OV 
delivery helps intratumoral 
propagation and persistence of virus, 
rendering more efficient therapy. 
[373] 
Murine teratocarcinoma 
(F9) and human 
rhabdomyo-sarcoma 
(A673) 
75 - >92% TAM depletion with 
Clodrolip. Combination therapy 
of Clodrolip plus a VEGF-
neutralizing antibody was most 
effective. 
First demonstration of TAM 
depletion. Tumor inhibition was 
accompanied by drastic anti-
angiogenic effects. CD11c+ TADCs 
were also depleted by Clodrolip or 
antibody treatment. 
[351] 
Zoledronate has also been encapsulated in liposomes either targeted to the folate 
receptor expressed on tumor cells showing cytotoxic activity [352] or in 
(polyethylene)glycol liposomes tested in murine models of human prostate cancer 
and multiple myeloma where the liposomal formulation proved to be more cytotoxic 
compared to the free drug [353]. Another study showed that treatment of 
hepatocellular carcinoma xenografts with sorafenib, a multikinase inhibitor, was 
markedly enhanced by concomitant depletion of macrophages by clodrolip or free 
zoledronate [354]. 
Drug formulations with liposomes are also used to target other cell types in the 
TME including the tumor cells themselves [355-357]. The high vascular 
permeability of tumor blood vessels can be exploited for increased accumulation 
and retention of macromolecules and liposomes in the tumor tissue. Passive 
targeting of long circulating liposomes to tumors with liposomal doxorubicin was 
one of the first clinically approved drug application with enhanced activity and 
reduced toxicity [358] and several other drugs are currently being evaluated as 
liposome formulations. 
Extravasation and accumulation of liposomal drugs within the TME occurs 
because small liposomes are able to penetrate through the leaky vasculature into 
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the tumor tissue where they are taken up by cells such as macrophages or 
dendritic cells or where they release the encapsulated payload into the ECM. In an 
earlier mouse tumor model study, we demonstrated the specificity and 
cytotoxicity of immunoliposomes that were targeted against the ED-B isoform of 
fibronectin which is uniquely expressed in the ECM of solid tumors [359]. 
Other examples of target-specific immunoliposomes are doxorubicin loaded anti-
HER2 immunoliposomes [360] or epidermal growth factor receptor (EGFR)-
targeted immunoliposomes [361]. In summary, nanocarriers, most notably 
liposomes, possess a great potential for the delivery of cytotoxic drugs or 
immunomodulating agents to the TME and to metastases [362]. 
Therapies Aimed at TANs 
To date, the anti-tumor potential of neutrophils has received scarce attention and 
their functions as effective weapons against cancer are still not fully exploited. 
Yet, recently gathered evidence indicates that under appropriate stimulation 
neutrophils reveal very powerful tumor-inhibitory properties. As neutrophils in 
tumor-bearing hosts have impaired cytotoxic activity, the development of 
methods that stimulate recruitment and anti-tumorigenic activation within a TME 
can be exploited as new therapeutic opportunities. 
Early studies with cytokine or chemokine gene transfected mammary 
adenocarcinomas in syngeneic tumor models indicated that nonspecific 
mechanisms, mostly supported by neutrophil functions, had much greater 
therapeutic power than those elicited by specific immunity [374-376]. For 
example, local or systemic administration of rIL-12 in mice bearing subcutaneous 
mammary carcinoma resulted in a rapid influx of neutrophils with high cytotoxic 
potential and anti-angiogenic function [377]. TGF- has been defined as a major 
functional regulator of neutrophils. Specifically in tumors, TGF- has been found 
to drive the pro-tumorigenic polarization of neutrophils. Thus, inhibition of TGF-
 signaling offers a means to manipulate neutrophil polarization by shifting N2-
TANs to tumor growth inhibiting N1-neutrophils. Additionally, TGF- receptor 
blockage in tumor bearing mice was shown to induce the activation of 
CD11b+Ly6G+ neutrophils that resulted in a significant tumor growth delay [263]. 
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Therapies Aimed at CAFs and Mast Cells 
CAFs represent another therapeutic target within the TME. However, due to a 
lack of compounds that specifically target this cell population, such strategies 
have not been widely used in the clinical setting. The most studied target 
molecule is the fibroblast activation protein (FAP) that is selectively expressed on 
stromal fibroblasts or on CAFs. FAP is a membrane-bound serine protease of the 
prolyl oligopeptidase family with distinctive endopeptidase activity and with low 
or undetectable expression in fibroblasts of normal tissues [378, 379]. In a 
preclinical vaccine approach, it was shown that immunological targeting of FAP 
can elicit protective immunity. A DNA vaccine directed against FAP suppressed 
primary tumor growth and pulmonary metastases primarily through CD8+ T-cell-
mediated killing in tumor-bearing mice [380]. 
Mast cells (MC) play an essential role as effector cells in allergy but they also 
contribute to tumor development. Activated MC located in the TME release 
angiogenic and tumor growth stimulating factors [124, 125, 381]. Recent findings 
indicate that tumor-associated mast cells might represent valuable targets for 
therapeutic interventions, most notably to kinase inhibitors as c-Kit [128, 382]. 
Other Therapies: Anti-angiogenic Therapies, Antibodies, Antibody-drug 
Conjugates, Cytokines, Gene Therapeutics 
The major non-cellular therapies aiming at specific targets in the TME including 
antibodies and small molecule inhibitors are summarized in the following section. 
Anti-Angiogenic Therapies 
The vascular endothelial growth factor (VEGF) proteins are key regulators of 
normal and tumor angiogenesis and they are therefore extensively studied as 
therapeutic targets [383]. Antibodies and fusion proteins targeting VEGF are the 
clinically approved bevacizumab (Avastin, Genentech) [384-386], r84 (AT001, 
Affitech AS), a human antibody which inhibits VEGF from binding to the VEGF-
receptor-2 and VEGF-trap which is a fusion protein containing the binding 
domains of the VEGF-receptors 1 and 2 fused to the human IgG Fc region [383]. 
However, anti-angiogenic therapies may be compromised by the finding that 
myeloid CD11b+Gr1+ cells which contribute to tumor angiogenesis render tumors 
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refractory to angiogenic blockade by VEGF antibodies. This CD11b+Gr1+-
mediated effect is driven by the protein Bv8 which, in turn, is up-regulated by G-
CSF. Thus, G-CSF may contribute to tumor refractoriness to anti-angiogenic 
therapies [66, 245, 387]. Different anti-angiogenic compounds such as small 
molecule tyrosine kinase inhibitors TKIs (e.g. sunitinib, sorafenib, imatinib, 
dasatinib, nilotinib and the proteasome inhibitor bortezomib) and other 
immunomodulatory drugs targeting VEGF or other pathways seem to be capable 
of modulating immune responses, in a positive as well as a harmful manner. 
Recent studies focused not only on their direct anti-tumor responses, but also on 
their influence on the TME, as well as on their effects on malignant and healthy 
cells. Thus, for an optimal clinical anti-cancer treatment, a better understanding of 
these immunomodulatory effects is essential [388]. 
Unfortunately, the initial expectations and optimism for therapies with anti-
angiogenic drugs targeting the VEGF signaling pathway were impeded by the 
limited clinical benefits. New data indicate that the unique characteristics of the 
tumor vasculature within the TME may hold the key for successful novel anti-
angiogenic therapies. The molecular and cellular alterations that maintain aberrant 
tumor angiogenesis represents novel targets for improving current anti-angiogenic 
strategies [389]. This so-called "vascular normalization" is characterized by 
attenuation of hyperpermeability, increased vascular pericyte coverage and a 
normalized basement membrane, resulting in the reduction of tumor hypoxia and 
interstitial fluid pressure. This improves the metabolic profile of the TME and the 
delivery and efficacy of therapeutics. Novel genetic and pharmacological 
approaches characterized key regulators of vascular normalization such as 
proteins that regulate tissue oxygen sensing and vessel maturation [45, 390-392]. 
Antibodies 
Monoclonal antibodies have considerably modified the therapy concepts in 
clinical oncology. Antibodies and smaller fragments such as antigen-binding 
fragments (Fab), single chain variable fragments (scFv) and smaller molecules are 
produced by recombinant technologies [393]. Antibodies possess several 
clinically relevant mechanisms of action. They can manipulate tumor-related 
signaling and various antibodies show immunomodulatory properties and, by 
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activation or inhibition of the immune system, they can induce antitumor immune 
responses [394, 395]. Specifically, Fc-receptor expressing immune cells mediate 
the killing of tumor cells by mAbs. Stimulation of these immune effector cells 
therefore represents an interesting strategy to improve the therapeutic efficacy of 
mAbs. The stimulation of natural killer cells, T cells, macrophages, or dendritic 
cells can be used to enhance antibody-dependent cellular cytotoxicity, 
phagocytosis or tumor vaccine effects [396]. Besides supporting development and 
strengthening of the adaptive immunity, therapeutic antibodies are able to trigger 
early anti-tumor events such as receptor blockade, cytostasis, apoptosis, 
complement-dependent cytotoxicity and/or antibody-dependent cytotoxicity [397-
399]. Bispecific antibodies are used to mount and sustain tumor-specific cellular 
responses or in radioimmunotherapy to improve target binding, selectivity, and 
efficacy [400-403]. A widely studied target is the cytotoxic T-lymphocyte-
associated antigen CTLA-4, also called CD152, which regulates T-cell activation. 
Antibodies that block the interaction of CTLA-4 with its ligands B7.1 and B7.2 
enhance immune responses, including antitumor immunity. The recently FDA-
approved anti-CTLA-4 antibody ipilimumab (Yervoy) and tremelimumab are the 
most advanced antibodies for the treatment of metastatic melanoma [404-408]. 
Antibody-Drug Conjugates 
The development of antibody-drug or antibody-enzyme immunoconjugates for a 
more specifically targeted and efficient delivery of active compounds to target 
tumor cells has been followed since more than three decades. Several 
immunoconjugates, particularly those that incorporate internalizing antibodies and 
tumor-selective linkers have demonstrated impressive activity in preclinical 
models. Immunoconjugates that deliver doxorubicin, maytansine and 
calicheamicin were among the first to be evaluated in clinical trials [409,410]. The 
immunoconjugate gemtuzumab ozogamicin (Mylotarg, CMA-676), a 
calicheamicin conjugate that targets CD33, has been approved by the Food and 
Drug Administration (FDA) in 2000 for treatment of acute myelogenous leukemia 
(AML). Although gemtuzumab ozogamicin improved survival in a subset of 
AML patients when combined with standard chemotherapy, the drug was recently 
withdrawn by the FDA due to safety concerns [411]. However, the cytotoxic 
activity of the immunoconjugate confirms that CD33 remains a possible 
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therapeutic target for AML. In recent years, significant progress owing to the 
optimization of several parameters, including mAb specificity, drug potency, 
linker technology, and the stoichiometry and molecular sites of attachment of 
conjugated drugs has been made. These developments have led to an increase of 
conjugates being tested clinically, three of which are currently in late stage 
clinical trials: brentuximab vedotin (SGN-35) for Hodgkin lymphoma; 
trastuzumab-DM1 for breast cancer and inotuzumab ozogamicin for non-Hodgkin 
lymphoma [412]. The immunoconjugate trastuzumab emtansine (T-DM1) is a 
tumor-activated prodrug resulting from the conjugation of the cytotoxic and 
antimitotic maytansine derivative DM1 with the humanized anti-HER2 mAb 
trastuzumab which has been used for the treatment of breast cancer for over 10 
years. The maytansinoids bind microtubules in a manner similar to the vinca 
alkaloids, but they block mitosis 20 to 100-fold more potently. Clinically, 
trastuzumab emtansine exhibited efficacy in patients with HER2+ metastatic 
breast cancer. Furthermore, preclinical studies have reported that trastuzumab 
emtansine potentiates the effect of several chemotherapeutic agents (carboplatin, 
5-fluorouracil and docetaxel), other antibodies as well as receptor tyrosine kinase 
and PI3K inhibitors. Many of these combinations are currently investigated in 
humans [413]. Phase I and II trials of T-DM1 as single agent and in combination 
with paclitaxel, docetaxel and pertuzumab have shown clinical activity and 
favorable safety profiles in HER2+ metastatic breast cancer patients. Additional 
combinations of T-DM1 with antitumor drugs and additional disease settings such 
as early-stage HER2+ breast cancer are also under investigation [414, 415]. 
Brentuximab vedotin (SGN-35) is a novel antibody-drug conjugate consisting of 
the anti-CD30 antibody cAC10 conjugated by a protease-cleavable linker to 
monomethyl-auristatin E, a potent microtubule blocking agent. In phase II trials, 
response rates of 75% in relapsed/refractory Hodgkin's lymphoma and 87% in 
relapsed/refractory systemic anaplastic large-cell lymphoma were recently 
reported. The impressive response rates and limited toxicity of brentuximab 
vedotin (SGN-35) are very promising for relapsed/refractory patients with few 
treatment options. In 2011, brentuximab vedotin was approved in the US for the 
treatment of Hodgkin lymphoma after failure of autologous stem cell transplant 
(ASCT) or after failure of multiagent chemotherapy regimens in ASCT-ineligible 
candidates and for the treatment of systemic anaplastic large-cell lymphoma after 
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failure of prior multiagent chemotherapy regimens [416]. The efficacy of 
brentuximab vedotin in other CD30 positive lymphomas is currently under 
investigation [417-419]. 
Radioimmunotherapy (RAIT) of non-Hodgkin lymphoma (NHL), a disease that is 
radiosensitive as well as readily accessible to the antibody conjugates using 
directly labeled MAbs is of current interest after approval of the radiolabeled anti-
CD20 MAbs 131I-tositumomab and 90Y-ibritumomab tiuxetan [420]. The high 
efficacy of RAIT was illustrated with the nearly 100% overall response rate 
obtained in a clinical trial using an investigational radiolabeled anti-CD22 MAb, 
90Y-epratuzumab. The advantage of pretargeted RAIT over directly labeled MAbs 
is continuing to be validated in preclinical models of lymphomas and solid 
tumors. The advantages of combining RAIT with radiation sensitizers, with 
immunotherapy or drug conjugates targeting different antigens are being studied 
clinically and preclinically [421]. 
Comprehensive and updated lists of therapeutic antibodies and conjugates 
including their status of clinical use can be found at the website of the 
international ImMunoGeneTics information system (IMGT) 
(http://www.imgt.org/mAb-DB/index) and in the “Marketed therapeutic 
antibodies compendium” [422]. 
Antibody-enzyme conjugates are directed at tumor-associated antigens to achieve 
site-specific activation of prodrugs to potent cytotoxic drugs. This "antibody-
directed enzyme prodrug therapy" (ADEPT) technology has attracted 
considerable interest since the concept was first described in 1987 [423]. A 
particular advantage of the ADEPT approach is that it may allow the use of 
extremely toxic and potent agents at very low concentrations. The principle of 
ADEPT therapy is to use a tumor-associated antigen specific antibody to target an 
enzyme to tumor cells. The enzyme should be retained in the tumor after 
clearance from blood and normal tissues. A nontoxic prodrug, which is a substrate 
for the enzyme is then applied and by cleaving of the enzyme-prodrug complex a 
potent cytotoxic agent is generated in the tumor tissue [424-426]. More recently, 
complementing the ADEPT technology, the promising approaches GDEPT (gene-
directed enzyme prodrug therapy) and PMT (prodrug monotherapy) have been 
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developed. GDEPT and PMT allow a selective release of cytotoxic agents from 
non-toxic prodrugs at the tumor site either by enzyme encoding genes or by 
exploiting physiological and metabolic aberrations in cancerous tissue [427]. 
Chemokines and Cytokines 
As mentioned, the TME contains chemokines and cytokines which are vital 
factors for the regulation of tumor growth, invasion and metastasis. Beyond 
activating tumor vascularization, infiltrating myeloid cells also promote tumor 
growth by creating a microenvironment that is rich in growth factors and pro-
inflammatory cytokines that stimulate proliferation and survival of neoplastic 
cells [26, 108, 428]. Chemokines/cytokines and their receptors represent potential 
targets for therapeutic intervention, either with antibodies or small molecule 
antagonists. On the other hand, due to the complexity of the TME, and the large 
number of chemokines/cytokines and receptors that are also expressed by normal 
cells, issues remain regarding the targetability of inhibitors and whether the 
redundancy of the system will compensate an inactivated chemokine/cytokine or 
its receptor [429, 430]. 
The most studied cytokines for cancer immunotherapy are the interleukins (IL). 
Ex vivo treatment of lymphocytes with IL-2 gives rise to lymphokine activated 
killer (LAK) cells and clinical studies in patients with advanced cancer showed 
that treatment with IL-2 alone or in combination with LAK cells mediate 
complete or partial regression of cancer, predominantly melanomas and renal cell 
carcinoma [269-273, 431]. More recently, several new interleukins, namely IL-12 
in ovarian cancer [432, 433], IL-15 in various experimental tumor models [434], 
IL-18 in metastatic melanoma [435] and IL-21 in early phase renal cell carcinoma 
and melanoma clinical trials [436] have been characterized that have considerable 
promise for future immunotherapy [437]. IL-15 binds to its specific receptor, IL-
15Rα, which is expressed on dendritic cells, monocytes and macrophages. IL-15 
induces differentiation and proliferation of T, B and natural killer cells. It also 
enhances the cytolytic activity of CD8+ T cells and induces CD8+CD44high 
memory T cells. Furthermore, IL-15 stimulates cell differentiation and 
immunoglobulin synthesis by B cells and induces maturation of dendritic cells 
[438]. IL-18 functions mainly as a co-stimulatory cytokine and its optimal 
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efficacy may be obtained in combination with other immunostimulatory 
therapeutics. Finally, IL-27 which is a member of the IL-6/IL-12 heterodimeric 
cytokine family acts on naive CD4+ T cells and plays pivotal roles as a 
proinflammatory cytokine and generation of CTLs. Recent studies revealed that 
IL-27 plays an important role in CD8+ T cells as well [439]. 
Lastly, the interferons (IFN) are cytokines with a long history of use as 
immunotherapeutic drugs. The initial use of interferons in cancer therapy was 
based on their growth inhibitory and immunomodulatory effects, and more 
recently they have been shown to possess cytotoxic and anti-angiogenic 
properties. However, the availability of novel alternative therapies have replaced 
IFN therapy in many cancers [440]. Interferon-α (IFN-α) is a type-I interferon 
which exerts multiple biological effects, including antiviral and antitumor 
activities in patients with defined types of cancer and viral diseases. A combined 
antiviral and antitumor effect of interferon is assumed to occur after surgical 
resection of hepatocellular carcinoma (HCC). Thus, IFN has a significant 
beneficial effect after curative treatment of HCC in terms of both survival and 
tumor recurrence [441]. Early preclinical studies demonstrated the importance of 
host immune mechanisms in the generation of long-lasting antitumor responses 
after type-I IFN treatment. More recent studies have revealed new 
immunomodulatory effects of IFN-α, including activities on T cells and dendritic 
cells. Overall, therapeutic strategies based on IFN-α include the use of these 
cytokines in vivo as immune adjuvants of cancer vaccines or their use ex vivo to 
generate DC-based vaccines and the combination of certain chemotherapy 
regimens with IFN-α [442-444]. Interferon-γ (IFN-γ) is a cytokine that acts on 
cell-surface receptors, activating transcription of genes that increase tumor 
immunogenicity, disrupt proliferative mechanisms and inhibit tumor 
angiogenesis. Current investigations of IFN-γ suggest that the cytokine has the 
potential to be used clinically in the treatment of brain tumors and as an adjuvant 
to other immunotherapeutic modalities [445]. The discovery of the interferon-λ 
(IFN-λ) family has considerably contributed the understanding of the role 
interferons play in viral infections and in cancer. The IFN-λ proteins, also termed 
interleukin-28 and -29, belong to the new type-III interferons. Type-III interferons 
are structurally similar to type-II IFN (IFN-γ) but functionally they are identical to 
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type-I IFN (IFN-α/β). The IFN-λ, have similar signaling pathways as IFN-α/β and 
they inhibit proliferation of tumor cells through cell cycle arrest or apoptosis. 
However, in contrast to type-I or -II IFNs, the response to type-III interferons is 
highly cell-type specific. Only epithelial cells and some immune cells respond to 
IFN-λ. This particular pattern of response is controlled by the differential 
expression of the IFN-λ receptor. Recently, the potent antitumor effects of IFN-λ 
were demonstrated, opening new opportunities for IFN therapy [446, 447]. 
Gene Therapeutics 
Although the significance of MHC class I-restricted cytotoxic T lymphocytes 
(CTLs) as effectors of anti-tumor immunity has widely been demonstrated, most 
human tumors lack MHC-I expression or are inadequately differentiated and 
poorly immunogenic, a culprit that limits successful T-cell based tumor-specific 
immunotherapy. To overcome these disadvantages, the genetic modulation of T-
lymphocytes using T cell receptor (TCR) transfer with tumor-specific TCR genes 
is an attractive strategy to generate anti-tumor responses, especially in large solid 
tumors. In this approach, the genes encoding a TCR specific for a defined antigen 
can be isolated from a T-cell clone and transduced to stimulated normal peripheral 
T-lymphocytes. This approach enables the redirection of the adaptive immune 
response against antigens of choice [448, 449]. A first demonstration of the 
fesability of this method was given by Morgan and coworkers who demonstrated 
that it is possible to transduce normal autologous PBLs from metastatic melanoma 
patients with a MART1-specific TCR and generate large numbers of MART1-
specific cells to be infused back to the patients [450]. However, several factors 
may hold back the clinical benefit of this approach, such as the type of cells to 
modulate the vector configuration or the safety of the procedure. 
The novel technique of RNA interference (RNAi), including small interfering 
RNA (siRNA), short hairpin RNA (shRNA) and microRNA (miRNA), mediate 
RNAi effects through the RNA inducible silencing complex RISC and represent 
attractive systems to be utilized as therapeutic tools [451]. Synthetic RNAs are 
nowadays widely used as tools for target validation and gene knock-down or 
knock-in. Presently, there is considerable interest for therapeutic applications of 
RNAi, particularly in areas of infectious disease and cancer. Preclinical data 
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demonstrate the efficacy of RNAi, for example knock-down of gene messages 
that are essential for tumor cell growth, metastasis, angiogenesis and 
chemoresistance, leading to anti-tumor effects. All types of RNA used for RNAi 
possess pharmacokinetic properties similar to single-stranded antisense 
oligonucleotides, but they are generally more robust than the latter [452, 453]. 
Despite all the potential of RNAi as a novel class of therapeutics, limited cellular 
uptake, low biological stability and unfavorable pharmacokinetic profiles are 
hampering their successful application in the clinic. Therefore, the translation of 
RNAi to the clinical setting is crucially dependent on the development of suitable 
delivery systems that improve their pharmacokinetic and biodistribution 
properties. Thus, delivery strategies for RNAi become the main hurdle that must 
be resolved prior to the full-scale clinical development of siRNA therapeutics 
[454-458]. As some examples, oncolytic adenoviral delivery of siRNA offers the 
potential benefits of restricted and renewable siRNA expression within the tumor 
microenvironment with an additive antitumor effect through viral oncolysis and 
siRNA-mediated oncogene silencing [459, 460]. Significant advances have been 
achieved with sterically stabilized lipid-based nanocarriers such as the stabilized 
nucleic acid lipid particles (SNALP). However, stabilization of nanocarriers with 
poly(ethylene glycol) (PEG) has not solved all problems associated with delivery 
of RNAi molecules. PEG modification weakens the internalization of the RNA 
molecules into the target cell and its subsequent escape from the endocytic 
pathway which reduces biological activity. To overcome such limitations novel 
exchangeable PEG-derivatized lipids can be used. After systemic administration, 
these lipids can be released from the nanoparticle surface. Additionally, the design 
and synthesis of cationic lipids that are more fusogenic and the use of 
internalizing targeting ligands have contributed to the emergence of novel lipid-
based nanoparticles with remarkable transfection efficiency [461]. Finally, a 
nanoparticle formulation consisting of liposome-protamine-hyaluronic acid nano-
particles (LPH-NP) for systemic delivery of siRNA to tumors has been developed 
in a self-assembling process. The LPH-NP was further modified by PEG or PEG-
anisamide lipids. Anisamide is a targeting ligand for the sigma receptor over-
expressed in B16F10 melanoma cells. The targeted LPH-NP silenced 80% of 
luciferase activity in metastatic B16F10 lung tumors after a single i.v. injection 
and also showed very little immunotoxicity [462]. 
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TME Mediated Drug Resistance 
Resistance against antitumor drugs and therapeutic radiation represents a 
tremendous challenge for most cancer therapies. It has been demonstrated by 
various experimental approaches that the mesenchymal TME provides a 
protective environment that obstructs drug or radiation access to the tumor cells or 
creates a permissive environment that supports for example the existence of 
cancer stem cell (CSC) niches where tumor cells overcome treatment- and cancer-
induced stresses [463-471]. Resistance of tumors to anticancer drugs is mostly 
attributed to gene mutations, amplification of the multidrug resistance genes, 
epigenetic changes that influence drug uptake and metabolism, or export of drugs 
from cells [472-474]. An important advance in the understanding of tumor 
multidrug resistance (MDR) came with the identification of the P-glycoproteins 
(ABC transporter family) and other related transporters that are expressed in 
cancer cells and orchestrate the efflux of drugs from cells [475-477]. Tumor cells 
can also undergo physiologic changes in response to extracellular acidosis, a 
consequence of high glycolytic flux and poor vascular perfusion, both of which 
contribute to drug resistance including reduced apoptotic potential, genetic 
alterations, and elevated P-glycoprotein levels. A low extracellular pH creates a 
physiological drug barrier described by an "ion trapping" phenomenon [478, 479]. 
In addition, unfavorable pharmacokinetics and -dynamics and the limited ability 
of cancer drugs to diffuse deeply into hypoxic tumor tissue and to accumulate in 
tumor cells at lethal concentrations contributes to the unsatisfactory efficacy of 
cancer therapy [480, 481]. 
Regarding the contribution of stromal cells in the induction of drug resistance, 
increased infiltration of macrophages and high cathepsin protease levels in TAM 
were found in tumors following chemotherapy with paclitaxel, etoposide and 
doxorubicin, suggesting that cathepsin-expressing macrophages protected tumor 
cells against drug-induced tumor cell death [482]. It was also reported that TAM 
and their expression of milk-fat globule-epidermal growth factor-VIII (MFG-E8) 
play a role in the regulation of CSC. MFG-E8 activates Stat3 and Sonic Hedgehog 
pathways in CSC and further amplifies their anticancer drug resistance in 
cooperation with IL-6 [483]. The contribution of cancer associated fibroblasts 
(CAF) in induction of drug resistance was recently demonstrated in a co-culture 
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study of estrogen receptor positive MCF7 breast cancer cells with fibroblasts 
showing that tamoxifen resistance was induced by CAF. The fibroblasts also 
protected MCF7 cells against apoptosis induced by other anticancer agents, such 
as doxorubicin and the PARP-1 inhibitor ABT-888 [484]. 
Work in several different cancers has suggested that the CSC population serves as 
a source of chemotherapy and radiation-therapy resistance within tumors. Several 
resistance mechanisms have been proposed, including amplified checkpoint 
activation and DNA damage repair as well as increased Wnt/β-catenin and Notch 
signaling. Targeted therapies against the DNA damage checkpoint or stem-cell 
maintenance pathways may sensitize CSC to radiation or other therapies. CSC 
may also play a role in the induction of angiogenesis as well as in the mechanisms 
of resistance towards anti-angiogenic agents [485]. The dynamics of cancer cell 
death in response to therapy was recently investigated by intravital microscopy of 
chemotherapy-treated mouse tumors allowing a dynamic analysis of drug 
distribution, cell death and tumor-stroma interactions. Thereby, associations 
between vascular leakage and response to doxorubicin, including improved 
response in MMP-9 knockout mice that had increased vascular leakage were 
observed. Furthermore, CCR2-dependent infiltration of myeloid cells after 
treatment and better response of Ccr2 null host mice to doxorubicin and cisplatin 
treatment was demonstrated [486]. 
In respect to anti-angiogenic therapies, inhibitors targeting the VEGF signaling 
pathways have demonstrated, in both preclinical and clinical settings, that the 
benefits are at best transitory and often followed by re-establishment of tumor 
growth and progression. Several findings support the notion that two modes of 
unconventional resistance underlie such results; either the mode of evasive 
resistance, which is an adaptation to circumvent the specific angiogenic blockade, or 
an intrinsic or pre-existing indifference towards anti-angiogenic drugs [487-490]. 
Emerging evidence indicates that anti-angiogenic agents may increase intratumor 
hypoxia by promoting vessel pruning and inhibiting neo-angiogenesis. Indeed, 
several studies have highlighted the possibility that VEGF and VEGF-receptor 
inhibition can promote an invasive metastatic switch, in part by creating an 
increasingly hypoxic tumor microenvironment. As a potential remedy, a number of 
therapeutic approaches have been investigated that target the hypoxic tumor 
compartment to improve the clinical outcome of anti-angiogenic therapy [491-493]. 
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Novel approaches to control drug resistance include functional genomics and 
proteomics [494,495]. RNA interference based screening provides a valuable 
opportunity for the examination of intrinsic and acquired resistance mechanisms. 
The availability of short interfering RNA libraries targeting genes allows performing 
large-scale screens to identify molecules that are involved in multidrug resistance 
pathways [496]. The emerging role of microRNAs as key gene expression regulators 
is also being explored in drug resistance research [497]. Finally, immunotherapy 
could represent an important adjuvant to treat MDR, as resistance to immunotherapy 
generally is unrelated to the classical mechanisms of resistance to cytotoxic agents. 
Immunotherapy to combat MDR could consist of direct immune attack against 
MDR positive cells, using MDR as an immune target to deliver cytotoxic drugs, 
taking advantage of other immune properties of MDR positive cells or application of 
immunotoxins expressed under MDR control [498, 499]. Regarding therapeutic 
approaches against drug resistance, nanodrug carriers, in particular liposomes, are 
widely explored [500-502]. Nanocarrier strategies for the reversal of resistance 
involve the alteration of drug efflux pumps and other resistance mechanisms. The 
methodologies involved include specific targeting of drugs and nucleotide 
therapeutics, improvement of cellular uptake and bioavailability of drugs with poor 
physicochemical characteristics. Multifunctional nanoparticulate systems consisting 
of a targeting moiety, encapsulated cytotoxic drugs and an element responsive to the 
TME to release the encapsulated therapeutics hold promise toward ways to improve 
cancer treatment [503-505]. 
CONCLUSION 
The cancer cell centric view of tumor progression largely ignored for a long time 
the fact that complex interactions between cancer cells and the cellular and 
molecular components of the tumor microenvironment tightly regulate and 
orchestrate tumor growth, metastatic dissemination and in many instances also the 
outcome of cancer therapies. Despite of continuous efforts, for many years cancer 
research largely focused on cancer-cell driven carcinogenesis and on 
understanding the mutations causing neoplastic cell transformations. But to 
provide new therapeutic strategies targeted at the immune components of the 
TME, it is critical to understand how these cells are altered during tumor 
progression and how they reciprocally influence tumor initiation, progression and 
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metastasis. The three mainstays of cancer therapy, surgical removal of tumor 
tissue, chemotherapy and radiotherapy will be complemented in the future by a 
fourth pillar, namely tumor immunotherapy and novel treatments aimed at the 
cellular and molecular components of the tumor microenvironment. Such novel 
strategies are urgently needed to complement the classical treatment modalities 
with more effective and patient tailored therapeutic approaches. 
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ABBREVIATIONS 
ADEPT = Antibody-directed enzyme prodrug therapy 
Arg = Arginase 
bFGF = Basic fibroblast growth factor 
BP = Bisphosphonate 
CAF = Cancer-associated fibroblast 
CCL = Chemokine (C–C motif) ligand 
CCR = Chemokine (C–C motif) receptor 
CSC = Cancer stem cell 
CSF-1 = Colony-stimulating factor 1 
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CTL = Cytotoxic T-lymphocyte 
CXCL = Chemokine (C–X–C motif) ligand 
DC = Dendritic cell 
EC = Endothelial cell 
ECM = Extracellular matrix 
EGF = Epidermal growth factor 
EGF = Epidermal growth factor 
EMT = Epithelial-mesenchymal transition 
FGF = Fibroblast growth factor 
GDEPT = Gene-directed enzyme prodrug therapy 
GM-CSF = Granulocyte–macrophage colony-stimulating factor 
Gr1 = Granulocyte differentiation antigen 
HGF = Hepatocyte growth factor 
HGF = Hepatocyte growth factor 
HIF-1 = Hypoxia inducible factor 1 
IFN-γ = Interferon γ 
IL = Interleukin 
iNOS = Inducible nitric oxide synthase 
LAK = Lymphokine activated killer cell 
LPS = Lipopolysaccharide 
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M1 = Classically activated macrophages 
M2 = Alternatively activated macrophages 
MC = Mast cell 
MDSC = Myeloid derived suppressor cell 
MHC = Major histocompatibility complex 
miRNA = MicroRNA 
MMP = Matrix metalloproteinase 
MR = Mannose receptor 
MSC = Mesenchymal stem cell 
N1 = Classically activated neutrophil 
N2 = Alternatively activated neutrophil 
N-BP = Nitrogen-containing bisphosphonate 
NF-κB = Nuclear factor kappaB 
NO = Nitric oxide 
non-N-BP = Non-nitrogen containing bisphosphonate 
PDGF = Platelet-derived growth factor 
PDGF = Platelet derived growth factor 
PMT = Prodrug monotherapy 
RAIT = Radioimmunotherapy 
RNAi = RNA interference 
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ROI = Reactive oxygen intermediate 
ROS = Reactive oxygen species 
shRNA = Short hairpin RNA 
siRNA = Small interfering RNA 
STAT = Signal transducer and activator of transcription 
TADC = Tumor-associated dendritic cell 
TAM = Tumor-associated macrophage 
TAN = Tumor-associated neutrophil 
TGF-α = Transforming growth factor α 
TGF-β = Transforming growth factor-β 
Th = Helper T-cell 
TIL = Tumor infiltrating leucocyte 
TME = Tumor microenvironment 
TNF-α = Tumor necrosis factor-α 
TNF-α = Tumor necrosis factor α 
Treg = Regulatory T-cell 
uPA = Urokinase-type plasminogen activator 
VEGF = Vascular endothelial growth factor 
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